NCT06934200View on ClinicalTrials.gov

Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

April 15, 2027

Study Completion Date

October 15, 2027

Conditions
Food Hypersensitivity
Interventions
DRUG

Omalizumab

omalizumab injections

Trial Locations (1)

21287

RECRUITING

Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER